TruActive MPC 85 Recognized by Dairy Foods Magazine

Tamarack Biotics’ TruActive MPC 85 product was recently recognized by Dairy Foods Magazine as a new milk-based protein today to be used in foods and beverages in the sports, early childhood and elderly nutrition categories.

The article describes the ultraviolet technology used to produce TruActive, as well as outlining our current trials.

Read the article here.

Tamarack Biotics obtains GRAS status for TruActive™ NF

Fresno, CA, March 1, 2017 – Tamarack Biotics LLC today announced the completion of a self-affirmed “Generally Recognized as Safe” (GRAS) for its TruActive NF product. This approval enables Tamarack to begin sales of the world’s first food ingredient that contains more immune active proteins than any other product available today.

Generally recognized as safe (GRAS) is an American Food and Drug Administration (FDA) designation that a chemical or substance added to food is considered safe by experts, and so is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements.

Bob Comstock, Tamarack Biotics CEO, stated, “Our patent pending process enables TruActive™ products to retain more of the natural compounds found in raw milk than ever before. Scientific research demonstrates that these compounds provide valuable benefits for sports and human nutrition alike. Tamarack is now conducting or planning three clinical trials to prove the benefits our products provide for elderly vaccine response, allergy prevention and therapeutic impact on asthma. The GRAS approval we received today represents a critical step in our ability to positively impact people’s health”.

 

About Tamarack Biotics

Tamarack Biotics develops and produces dairy-based food ingredients that retain more of the immune active proteins and other thermally sensitive compounds than any other food ingredient. Tamarack Biotics utilizes non-thermal pathogen reduction and low-temperature drying technologies that fully dry milk and milk concentrates into stable powders at temperatures low enough to protect the thermally sensitive compounds, while achieving the same safety standards as traditionally pasteurized products.

Disclaimer

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those other than historical statements of fact, and can be identified by words such as “believes,” “projects,” “anticipates,” “forecasts,” and the like. These statements are based on the Companyʼs estimates, beliefs and assumptions as of the date of this press release and are not a guarantee of any future performance. Forward-looking statements are subject to certain known risks and uncertainties, which are detailed in the Companyʼs periodic filings with the SEC available at www.sec.gov. Management undertakes no obligation to update information contained herein, which is subject to change without notice.

Tamarack Biotics Announces Production Commencement of TruActive™ MPC 85

Fresno, CA 12 December 2016 – Tamarack Biotics announced today the production initiation of its TruActive™ MPC 85 product. “Using innovative new technologies to nearly eliminate the damage done by thermal pasteurization and high-temperature spray drying has always been our goal”, stated Bob Comstock, Tamarack Biotics CEO. “Today we went from the product development phase to the production scale phase and are prepared to supply our customers with the quantities of products they require. This phase proves the commercial viability of our patent-pending process and puts Tamarack Biotics in the unique position of being the only company offering a food ingredient that contains significant quantities of immune active proteins”.

Mr. Comstock further clarified, “Together with our equipment and manufacturing partners we have developed a state-of-the-art process utilizing the latest systems to ensure the safety, consistency and quality of our products.”

 

About Tamarack Biotics

Tamarack Biotics develops and produces dairy-based food ingredients that retain more of the immune active proteins and other thermally sensitive compounds than any other food ingredient. Tamarack Biotics utilizes non-thermal pathogen reduction and low-temperature drying technologies that fully dry milk and milk concentrates into stable powders at temperatures low enough to protect the thermally sensitive compounds, while achieving the same safety standards as traditionally pasteurized products.

Disclaimer

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those other than historical statements of fact, and can be identified by words such as “believes,” “projects,” “anticipates,” “forecasts,” and the like. These statements are based on the Company’s estimates, beliefs and assumptions as of the date of this press release and are not a guarantee of any future performance. Forward-looking statements are subject to certain known risks and uncertainties, which are detailed in the Company’s periodic filings with the SEC available at www.sec.gov. Management undertakes no obligation to update information contained herein, which is subject to change without notice.

 

Tamarack Biotics TruActive™ MPC 85 Featured at International Milk Genomics Conference

Fresno, CA 29 October 2016 – Today at the UC Davis hosted, International Milk Genomics Conference, Dr. Kasper Hettinga, of Wageningen University in the Netherlands, presented a paper on titled Damage to potential allergy-preventing proteins by regular heating and UVC treatment, which featured results from research jointly conducted by Dr. Hettinga and Tamarack Biotics. Dr. Hettinga’s results demonstrated the ability of UVC to protect the immune active proteins, which are thought to be responsible for raw milk’s ability to prevent children from developing allergies.

Bob Comstock, Tamarack Biotics CEO stated, “the research conducted by The PASTURE Team including Erika von Mutius of University Hospital Munich, clearly demonstrated that raw milk consumption, as opposed to living on a farm, prevented children from developing allergies. We hope to extend this research into a commercial product that contains these same allergy-preventing compounds through our innovative non-thermal pathogen reduction and low-temperature drying technologies. Dr. Hettinga’s work proves the ability of UVC to protect these immune active proteins, which are thought to be responsible for raw milk’s allergy preventing ability”.

 

About Tamarack Biotics

Tamarack Biotics develops and produces dairy-based food ingredients that retain more of the immune active proteins and other thermally sensitive compounds than any other food ingredient. Tamarack Biotics utilizes non-thermal pathogen reduction and low-temperature drying technologies that fully dry milk and milk concentrates into stable powders at temperatures low enough to protect the thermally sensitive compounds, while achieving the same safety standards as traditionally pasteurized products.

Disclaimer

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those other than historical statements of fact, and can be identified by words such as “believes,” “projects,” “anticipates,” “forecasts,” and the like. These statements are based on the Company’s estimates, beliefs and assumptions as of the date of this press release and are not a guarantee of any future performance. Forward-looking statements are subject to certain known risks and uncertainties, which are detailed in the Company’s periodic filings with the SEC available at www.sec.gov. Management undertakes no obligation to update information contained herein, which is subject to change without notice.

Tamarack Biotics initiates Immunosenescence Clinical Trial with TruActive™ MPC 85

Fresno, CA, 2 Aug 2016 – Tamarack Biotics today announced the initiation of its first clinical trial testing TruActive™ MPC 85’s ability to improve vaccine reponse in the elderly. The double-blind, placebo-controlled clinical trial, conducted in conjunction with UC Davis, will investigate whether elderly Pertussis vaccine response can be improved through the use of Tamarack Biotic’s immune active protein containing product.

Researchers have known for years that immune response diminishes with age, and by the time people turn 70, only half generate the intended antibodies from a flu shot or similar vaccine. This condition, termed Immunosenescence, highlights a serious health issue for the country’s aging population. Bob Comstock, Tamarack Biotics CEO, stated “We expect to demonstrate that elderly people can remain healthier through the consumption of immune active proteins, which have never before been available. The TruActive™ line of products are the only food ingredients that contain these immune active proteins, which we believe will reduce health care costs by keeping people well”.

Mr. Comstock further stated, “the initiation of this clinical trial, with 50 subjects over the age of 60, marks an important milestone in our mult-faceted clinical trial program”. Tamarack Biotics intends to demonstrate the valuable benefits provided by immune active proteins for sports nutrition, allergy prevention and elderly health”.

 

About Tamarack Biotics

Tamarack Biotics develops and produces dairy-based food ingredients that retain more of the immune active proteins and other thermally sensitive compounds than any other food ingredient. Tamarack Biotics utilizes non-thermal pathogen reduction and low-temperature drying technologies that fully dry milk and milk concentrates into stable powders at temperatures low enough to protect the thermally sensitive compounds, while achieving the same safety standards as traditionally pasteurized products.

Disclaimer

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those other than historical statements of fact, and can be identified by words such as “believes,” “projects,” “anticipates,” “forecasts,” and the like. These statements are based on the Companyʼs estimates, beliefs and assumptions as of the date of this press release and are not a guarantee of any future performance. Forward-looking statements are subject to certain known risks and uncertainties, which are detailed in the Companyʼs periodic filings with the SEC available at www.sec.gov. Management undertakes no obligation to update information contained herein, which is subject to change without notice.